Departamento de Clínica Médica, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil, Montreal Chest Institute & McGill International TB Centre, McGill University, Montreal, QC, Canada.
WHO Collaborating Centre, Novosibirsk Tuberculosis Research Institute, Novosibirsk, Russian Federation.
Int J Tuberc Lung Dis. 2022 Aug 1;26(8):710-719. doi: 10.5588/ijtld.22.0006.
Together, SARS-CoV-2 and have killed approximately 5.7 million people worldwide over the past 2 years. The COVID-19 pandemic, and the non-pharmaceutical interventions to mitigate COVID-19 transmission (including social distancing regulations, partial lockdowns and quarantines), have disrupted healthcare services and led to a reallocation of resources to COVID-19 care. There has also been a tragic loss of healthcare workers who succumbed to the disease. This has had consequences for TB services, and the fear of contracting COVID-19 may also have contributed to reduced access to TB services. Altogether, this is projected to have resulted in a 5-year setback in terms of mortality from TB and a 9-year setback in terms of TB detection. In addition, past and present TB disease has been reported to increase both COVID-19 fatality and incidence. Similarly, COVID-19 may adversely affect TB outcomes. From a more positive perspective, the pandemic has also created opportunities to improve TB care. In this review, we highlight similarities and differences between these two infectious diseases, describe gaps in our knowledge and discuss solutions and priorities for future research.
在过去的两年中，SARS-CoV-2 和 共同导致全球约 570 万人死亡。COVID-19 大流行以及为减轻 COVID-19 传播而采取的非药物干预措施（包括社交距离规定、部分封锁和隔离）扰乱了医疗服务，并导致资源重新分配用于 COVID-19 护理。也有大量医护人员因感染该疾病而丧生。这对结核病服务产生了影响，而且对感染 COVID-19 的恐惧也可能导致结核病服务的获取减少。总的来说，预计这将导致结核病死亡率倒退 5 年，结核病检出率倒退 9 年。此外，过去和现在的结核病报告显示，这两种传染病都会增加 COVID-19 的病死率和发病率。同样，COVID-19 也可能对结核病的结果产生不利影响。从更积极的角度来看，大流行也为改善结核病护理创造了机会。在这篇综述中，我们强调了这两种传染病的相似之处和不同之处，描述了我们知识上的差距，并讨论了未来研究的解决方案和优先事项。
